Sphingosine kinase 1 plays a role in the upregulation of CD44 expression through extracellular signal-regulated kinase signaling in human colon cancer cells

Anti-Cancer Drugs

Volumn 24, Issue 5, 2013, Pages 473-483

  Kawahara, Satomi ^a   Otsuji, Yoko ^a   Nakamura, Mitsuhiro ^b   Murakami, Masashi ^d   Murate, Takashi ^e   Matsunaga, Toshiyuki ^a   Kanoh, Hiroyuki ^c   Seishima, Mariko ^c   Banno, Yoshiko ^c   Hara, Akira ^a  

^a Departments of Biochemistry   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^c GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^e NAGOYA UNIVERSITY   (Japan)

Author keywords

CD44; colon cancer cell; extracellular signal regulated kinase signaling; oxaliplatin resistance; sphingosine kinase 1

Indexed keywords

COMPLEMENTARY DNA; HERMES ANTIGEN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OXALIPLATIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; RECEPTOR BLOCKING AGENT; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE 1;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL STRAIN HCT116; COLON CANCER; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENETIC TRANSFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTIGENS, CD44; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HCT116 CELLS; HUMANS; LYSOPHOSPHOLIPIDS; ORGANOPLATINUM COMPOUNDS; PHOSPHORYLATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SPHINGOSINE; UP-REGULATION;

EID: 84875843519     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835f705f     Document Type: Article

References (43)

1. Pettus BJ, Chalfant CE, Hannun YA. Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta 2002; 1585:114-125. (Pubitemid 36092075)
2. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003; 4:397-407. (Pubitemid 36565571)
3. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4:604-616. (Pubitemid 39025055)
4. Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 2006; 1758:2016-2026. (Pubitemid 44879368)
5. Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM, et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 2007; 282:10922-10934. (Pubitemid 47100788)
6. Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S, et al. Sphingosine kinase expression increases intracellular sphingosine-1- phosphate and promotes cell growth and survival. J Cell Biol 1999; 147:545-558.
7. Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res 2003; 47:401-407. (Pubitemid 36379202)
8. Milstien S, Spiegel S. Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics. Cancer Cell 2006; 9:148-150. (Pubitemid 43357940)
9. Young N, Van Brocklyn Jr. Signal transduction of sphingosine-1-phosphate G protein-coupled receptors. ScientificWorld J 2006; 6:946-966. (Pubitemid 44252720)
10. French KJ, Schrecengost RS, Lee B, Zhuang Y, Smith SN, Eberly JL, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63:5962-5969. (Pubitemid 37187498)
11. Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res 2005; 65:11667-11675. (Pubitemid 41821727)
12. Taha TA, Hannun YA, Obeid LM. Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 2006; 39:113-131.
13. Kawamori T, Osta W, Johnson KR, Pettus BJ, Bielawski J, Tanaka T, et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 2006; 20:386-388. (Pubitemid 46671180)
14. Xia P, Wang L, Gamble JR, Vadas MA. Activation of sphingosine kinase by tumor necrosis factor-a inhibits apoptosis in human endothelial cells. J Biol Chem 1999; 274:34499-34505. (Pubitemid 129511798)
15. Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T, et al. High expression of sphingosine kinase 1 and S1P receptors in chemotherapyresistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem Biophys Res Commun 2006; 342:1284-1290.
16. Sobue S, Iwasaki T, Sugisaki C, Nagata K, Kikuchi R, Murakami M, et al. Quantitative RT-PCR analysis of sphingolipid metabolic enzymes in acute leukemia and myelodysplastic syndromes. Leukemia 2006; 20:2042-2046. (Pubitemid 44614898)
17. Sobue S, Nemoto S, Murakami M, Ito H, Kimura A, Gao S, et al. Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat; relevance as a marker for daunorubicin sensitivity of leukemia cells. Int J Hematol 2008; 87:266-275.
18. Nemoto S, Nakamura M, Osawa Y, Kono S, Itoh Y, Okano Y, et al. Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. J Biol Chem 2009; 284:10422-10432.
19. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2003; 414:105-111. (Pubitemid 33041634)
20. Dick JE. Breast cancer stem cells revealed. Proc Natl Acad Sci USA 2003; 100:3547-3549. (Pubitemid 36418067)
21. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumor initiating cells. Nature 2004; 432:396-401. (Pubitemid 39551674)
22. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006; 66:9339-9344. (Pubitemid 44623625)
23. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445:111-115. (Pubitemid 46067311)
24. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61:1303-1313.
25. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol 1993; 54:271-335. (Pubitemid 23289255)
26. Subramaniam V, Vincent IR, Gardner H, Chan E, Dhamko H, Jothy S. CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation. Exp Mol Pathol 2007; 83:207-215. (Pubitemid 47320661)
27. Shimabukuro Y, Terashima H, Takedachi M, Maeda K, Nakamura T, Sawada K, et al. Fibroblast growth factor-2 stimulates directed migration of periodontal ligament cells via PI3K/AKT signaling and CD44/hyaluronan interaction. J Cell Physiol 2011; 226:809-821.
28. Thomas L, Byers HR, Vink J, Stamenkovic I. CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol 1992; 118:971-977.
29. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11:254-267.
30. Su YJ, Lai HM, Chang YW, Chen GY, Lee JL. Direct reprogramming of stem cell properties in colon cancer cells by CD44. EMBO J 2009; 30:3186-3199.
31. Hong SP, Wen J, Bang S, Park S, Song SY. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 2009; 125:2323-2331.
32. Stordal BK, Davey MW, Davey RA. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells. Cancer Chemother Pharmacol 2006; 58:256-265.
33. Tolg C, Hofmann M, Herrlich P, Ponta H. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res 1993; 21:1225-1229. (Pubitemid 23155620)
34. Bourguignon LY, Gunja-Smith Z, Iida N, Zhu HB, Young LJ, Muller WJ, et al. CD44v3,8-10 is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol 1998; 176:206-215. (Pubitemid 28277210)
35. Tanimura S, Asato K, Fujishiro SH, Kohno M. Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix- 3/-9/-14 and CD44. Biochem Biophys Res Commun 2003; 304:801-806. (Pubitemid 36513560)
36. Judd NP,Winkler AE, Murillo-Sauca O, Brotman J, Law JH, Lewis JS, et al. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res 2012; 72:365-374.
37. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, et al. Growthinhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008; 134:62-73. (Pubitemid 351905743)
38. Loveridge C, Tonelli F, Leclercq T, Lim KG, Long JS, Berdyshev E, et al. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J Biol Chem 2010; 285:38841-38852.
39. Taha TA, Osta W, Kozhaya L, Bielawski J, Johnson KR, Gillanders WE, et al. Down-regulation of sphingosine kinase-1 by DNA damage. J Biol Chem 2004; 279:20546-20554.
40. Taha TA, Kitatani K, Bielawski J, Cho W, Hannun YA, Obeid LM. Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. J Biol Chem 2005; 280:17196-17202. (Pubitemid 41389186)
41. Heffernan-Stroud LA, Helke KL, Jenkins RW, De Costa A M, Hannun YA, Obeid LM. Defining a role for sphingosine kinase 1 in p53-dependent tumors. Oncogene 2012; 31:1166-1175.
42. Pitson SM, Moretti PA, Zebol JR, Lynn HE, Xia P, Vadas MA, et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J 2003; 22:5491-5500. (Pubitemid 37279958)
43. Jarman KE, Moretti PA, Zebol JR, Pitoson SM. Translocation of sphingosine kinase 1 to the plasma membrane is mediated by calcium- and integrinbinding protein 1. J Biol Chem 2010; 285:483-492.